A serious adverse event (SAE) is an untoward medical occurrence in a clinical trial that fulfills a defined seriousness criterion. These include death, life-threatening situation, inpatient hospitalization or prolongation thereof, persistent or significant disability, congenital anomaly, or birth defect. SAE reporting is a central process of clinical pharmacovigilance and serves the protection of participants.<\/p>\n
Regulation (EU) No 536\/2014 defines an SAE as any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, or is a congenital anomaly or birth defect. ICH E2A adds that medically important events may also be classified as serious if they do not immediately result in the listed consequences but may require intervention to prevent such consequences.<\/p>\n
“Serious” does not describe the same thing as the clinical intensity of a symptom. A severe, but not criterion-meeting event can be medically severe without being an SAE. Conversely, an event with low symptom intensity can be an SAE if, for instance, it requires inpatient hospitalization. The classification must therefore be based on the defined seriousness criteria and not solely on designations such as “mild”, “moderate”, or “severe”.<\/p>\n
The investigator documents the safety-relevant information at the investigator site and reports SAEs occurring in participants treated by him or her to the sponsor, provided the protocol does not stipulate a different rule for specific SAEs. According to Article 41 of Regulation (EU) No 536\/2014, the report is made without undue delay and at the latest within 24 hours of obtaining knowledge. Required follow-up reports enable the sponsor to assess the impact on the benefit-risk balance of the trial.<\/p>\n
The sponsor evaluates the incoming information, in particular causality and expectedness. Only when a serious event is concurrently assessed as an adverse reaction and is unexpected does a SUSAR exist. For SUSARs, the expedited electronic reporting timeframes under Article 42 apply: for fatal or life-threatening cases as soon as possible, no later than seven days after the sponsor’s knowledge; for non-fatal and non-life-threatening cases no later than 15 days thereafter.<\/p>\n
The reporting of an SAE to the sponsor is thus not synonymous with a SUSAR report to the EMA database. The initial report ensures that all important safety information converges at the sponsor. The subsequent medical-regulatory evaluation decides whether an expedited SUSAR report is triggered and what further measures, such as a protocol adaptation or informing the investigator sites, are necessary.<\/p>\n
An adverse event (AE) is the overarching term. It designates an untoward medical occurrence presenting in a person in a clinical trial, without necessarily implying a causal relationship with the medicinal product. An SAE is an AE that fulfills at least one of the statutory seriousness criteria. Every SAE is therefore an adverse event, but not every adverse event is serious.<\/p>\n
An adverse reaction, in contrast to the AE, presupposes an at least suspected causal relationship with the medicinal product. An SAE can consequently initially be recorded without a suspected relationship to the investigational medicinal product. If a relationship is assumed, it is a serious adverse reaction. Causality assessment is a technical evaluation and must consider the available clinical information.<\/p>\n
A SUSAR is defined more narrowly than an SAE. It is a suspected unexpected serious adverse reaction. “Unexpected” means that the nature or severity of the reaction is not consistent with the available safety information on the investigational medicinal product. Therefore, not every SAE and not every serious adverse reaction triggers a SUSAR report.<\/p>\n
SAE processes must function at the investigator site and at the sponsor from the first participant onwards. Clear contact pathways, the 24-hour reporting requirement, a traceable follow-up process, and prompt medical evaluation make it possible to identify safety risks and maintain oversight of the trial. Monitoring checks in particular whether SAEs were fully documented in the source, case report form, and safety documents, as well as transmitted within the deadline.<\/p>\n
Full-service CROs such as Mediconomics provide support with study processes for pharmacovigilance, SAE recording and follow-up, training of the investigator sites, safety data management, medical documentation, and quality controls. The collaboration of clinical operations, monitoring, medical writing, and regulatory affairs helps to consistently assess safety information, escalate in a timely manner, and compile regulatory reports traceably.<\/p>\n
Is every adverse event an SAE?<\/strong><\/p>\n No. An adverse event is the broader term and does not require a causal relationship. An SAE only exists if at least one of the defined seriousness criteria is fulfilled. Clinical intensity alone does not decide the SAE classification.<\/p>\n When does an SAE become a SUSAR?<\/strong><\/p>\n An SAE becomes a SUSAR if there is additionally a suspected relationship with the investigational medicinal product and the reaction is unexpected. The assessment of causality and expectedness is based on the available safety information; only SUSARs are subject to expedited reporting under Article 42 of Regulation (EU) No 536\/2014.<\/p>\n Within what timeframe must an SAE be reported to the sponsor?<\/strong><\/p>\n The investigator reports SAEs to the sponsor according to Article 41 of Regulation (EU) No 536\/2014 without undue delay and at the latest within 24 hours of obtaining knowledge, provided the protocol does not stipulate a different rule for specific SAEs. This timeframe is to be distinguished from the seven- or 15-day timeframes for SUSAR reporting by the sponsor.<\/p>\n A serious adverse event (SAE) is an untoward medical occurrence in a clinical trial that fulfills a defined seriousness criterion. These include death, life-threatening situation, inpatient hospitalization or prolongation thereof, persistent or significant disability, congenital anomaly, or birth defect. SAE reporting is a central process of clinical pharmacovigilance and serves the protection of participants. Definition […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[],"class_list":["post-6665","glossary","type-glossary","status-publish","hentry"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6665","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":1,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6665\/revisions"}],"predecessor-version":[{"id":7484,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6665\/revisions\/7484"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=6665"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=6665"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory references<\/h2>\n
\n